UNSPSC 51182107: Conivaptan hydrochloride

This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75L57R6X36, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but more generally known as conivaptan hydrochloride, which bears US NIH Compound Identifier 151171. Most nations, for tariff and trade purposes, schedule conivaptan hydrochloride under HS 29339930 and SITC 51577.

As of Q4 2014, CONIVAPTAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Conivaptan hydrochloride bears US NLM identifiers UMLS ID C1700196 and NCI Concept Code C65351. SMILES: CC1[NH]C-2C(N1)CCN(C3C2CCCC3)C(=O)C4CCC(CC4)NC(=O)C5CCCCC5C6CCCCC6.CL.

UNSPSC 51182107 Conivaptan hydrochloride is a Commodity code capturing pharmaceutical supply under state and local cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities, including Oregon. State and local agencies buy pharmaceutical products under this code as part of bulk purchasing arrangements that consolidate demand across multiple jurisdictions to achieve pricing leverage. Vendors supplying under this code must meet cGMP certification, comply with the Drug Supply Chain Security Act, maintain insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with chargeback systems in place. Products must be FDA-compliant with expiration dates of at least one year from manufacture and a minimum six-month shelf life.

MMCAP represents a multistate cooperative purchasing vehicle anchored by Minnesota and including Oregon among participating members. The RFP for generic multi-source pharmaceuticals and OTC products was issued January 20, 2026, with a response deadline of March 26, 2026, and a question cutoff date of February 18, 2026. Award is scheduled for May 15, 2026, with contracts effective July 1, 2026, for a two-year initial term with optional extensions at MMCAP's sole discretion. Evaluation criteria emphasize price competitiveness (75 percent weight), with secondary weight on fixed pricing for the contract term (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The solicitation does not identify specific set-aside or disadvantaged-enterprise restrictions. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs, with performance penalties ranging from $200 to $1,500 per violation for reporting failures, missed onboarding timelines, or improper class-of-trade denials.